Triple Versus Quadruple Therapy for the Eradication of Helicobacter Pylori
The study aimed to compare the efficacy and safety of 7-day and 14-day vonoprazan-amoxicillin-tetracycline triple therapy with 14-day vonoprazan-amoxicillin-tetracycline-bismuth quadruple therapy for the eradication of Helicobacter pylori. Subjects were randomized to receive the intervention and were reviewed by 13C-urea breath test after 6 weeks. The eradication rates, adverse reaction rates and patient adherence were calculated.
- EligibilityCriteria: Inclusion Criteria:  Patients aged 18-70 years old; Patients with H.pylori infection (positive rapid urease test, 13C/14C-urea breath test); Patients without previous treatment for H. pylori eradication.  Exclusion Criteria:  Patients with serious underlying diseases, such as liver insufficiency (Aspartate aminotransferase or alanine aminotransferase greater than the normal value), renal insufficiency (Cr≥2.0mg/dL or glomerular filtration rate <50 ml/min), immunosuppression, malignant tumors, Coronary heart disease or coronary artery stenosis ≥75%; Patients with active gastrointestinal bleeding; Patients with a history of upper gastrointestinal surgery; Patients allergic to treatment drugs; Patients with medication history of bismuth, antibiotics within 4 weeks, or proton pump inhibitor within 2 weeks; Patients who are pregnant or lactating or unwilling to take contraceptive measures during the trial; Patients with other behaviors that may increase the risk of illness, such as alcohol and drug abuse; Patients who are unwilling or incapable to provide informed consents. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult